Phaseline

Companies › Novita Pharmaceuticals

Novita Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NP-G2-044 (Prilukae)
unclear - mechanism not specified in registry text
–Phase 2Platinum-resistant Ovarian Cancer; Advanced or Metastatic Solid Tumor MalignanciesOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05023486NP-G2-044 (Prilukae)Phase 1Advanced or Metastatic Solid Tumor MalignanciesOncologyJun 2026
NCT07109414NP-G2-044 (Prilukae)Phase 2Platinum-resistant Ovarian CancerOncologyOct 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.